MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards
MyGuava in association with Crystal Palace Football Club is thrilled to launch exclusive Crystal Palace Fan Cards with rewards and a variety of perks as well as a unique opportunity for fans to celebrate their connection to the club while enjoying MyGuava’s seamless payment solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101068560/en/
MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards (Photo: Business Wire)
Palace fans can now download the MyGuava App and order a Crystal Palace Card, choosing from three custom-designed cards: ‘Palace Gold’, ‘Palace Sash’ and ‘Selhurst 100’.
Each card comes packed with perks, including entry into exclusive prize draws, cashback on all purchases, giving Palace fans an opportunity to take advantage of the 7% cashback offer ahead of the festive period. Additionally, the cards come with Visa Platinum status for added financial flexibility.
Furthermore, for the most dedicated Eagles supporters, 900 limited-edition ‘Palace Gold’ cards will be available on a first come first served basis, offering enhanced cashback rates and special access to exclusive club benefits.
Rewards System
The MyGuava and Crystal Palace card will also be introducing a multi-stage reward system, providing cardholders with the exciting chance to earn Crystal Palace merchandise and experience based on spending. Supporters can win Crystal Palace branded bottles, t-shirts, hoodies as well as stadium tours and even personalised messages from the team for completing transaction milestones.
The MyGuava App, which is the flagship product of Guavapay, is designed to meet the broad financial needs of users. Users can open accounts in 20 currencies, make seamless local and global transfers, and use both virtual and physical debit cards. The App also has significant global reach, with access to 140 countries in more than 90 currencies and there are additional benefits with discounted gift cards from top brands and tools for enhancing user experience, such as digital skins, spending management tools and vaults.
To learn more about the Crystal Palace Card and Reward scheme, please visit the link below:
https://myguava.com/personal/landings/crystalpalace-cobrand-card
About Guavapay
Guavapay is a global fintech company with headquarters in London. The company has built a global financial ecosystem to empower individuals and businesses and give them more control over their financial lives. The All Things Payments App, MyGuava and the B2B platform, MyGuava Business simplify financial services, making them more accessible and affordable for people who have historically been overlooked.
The MyGuava Application is owned and operated by Guavapay Limited, a company registered in England with company number 10601900 and its registered address at Salisbury House, 29 Finsbury Circus, London, EC2M 5QQ, United Kingdom. Guavapay Limited is registered with the Financial Conduct Authority in the United Kingdom as a Small Electronic Money Institution with reference number 900888. Guavapay Limited’s ICO registration number is ZA274504.
For more information, please visit www.guavapay.com or contact:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101068560/en/
Contacts
Media Contacts:
Kieran McDonagh
Email - kieran.mcdonagh@guavapay.com
Rajeshwari Channakrishna
Email – rajeshwari.channakrishna@guavapay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision5.11.2024 00:18:00 EET | Press release
LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug Administration (FDA) has authorized marketing of Valeda® Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD), a leading cause of central vision loss in people over 55 in developed countries. The Valeda therapy is the first ever authorized treatment by the FDA for vision loss in dry AMD patients. Valeda provides an improvement in best corrected visual acuity (BCVA) over 24 months of >5 letters or equivalent to a line on the eye chart. In the pivotal U.S. LIGHTSITE III trial, the Valeda treatment met its primary endpoint and was shown to be safe and effective in increasing and maintaining improved visual acuity. LumiThera submitted the US LIGHTSITE III clinical data as part of a technical package to the FDA under a De Novo request with special controls. “The De Novo authorization established Va
Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria4.11.2024 22:12:00 EET | Press release
Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/ Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Pri
Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings4.11.2024 21:50:00 EET | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/ Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire) “Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executiv
Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years4.11.2024 18:10:00 EET | Press release
Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future. Key findings from the 2024 survey include: More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 months Insurers still need to move beyond legacy systems and fully modernize their operations, yet 49% admit they are behind schedule “This year’s su
Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei4.11.2024 18:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch and availability of Evercode™ Low Input Fixation kits for both cells and nuclei. The new kits empower researchers who have a small number of starting cells or nuclei who ordinarily might not be able to perform single cell sequencing using fixed cells. Fixation is a strategy used by many single cell researchers because it enables them to collect samples at different times and then perform library preparation and sequencing at once when all of the samples are amassed. Yet, a well-known challenge across all fixation technologies is that they require a certain number of cells or nuclei, usually 50,000 or greater. With the new kits from Parse, researchers can start with as few as 10,000 cells or nuclei. The new low input fixation kits are ideal for researchers working with limited cells across various conditions or those handling rare and precious samples. These kits
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom